You are here: Home » PTI Stories » National » News
Business Standard

Tatan Tata invests in pharma start-up Generic Aadhaar

Health Medical Pharma

Press Trust of India  |  Mumbai 

Ratan Tata, who has pumped in hundreds of crores of rupees into start-ups since his retirement from the Tata Group, has invested an undisclosed amount in a 17-year-old kid's pharma start-up Generic Aadhaar, in his personal capacity.

Generic Aadhaar was founded by the Thane kid, Arjun Deshpande, in April 2019, when he was 16. It supplies quality generic drugs from reputed manufacturers at up to 80 per cent lesser cost and other medicines 20-30 per cent cheaper.

The boy, an alumni of DAV Public School, Thane, began his entrepreneurial journey with the aim of bringing affordable medicines to the poor, a statement issued by his PR agency said on Thursday.

It did not disclose how much Tata has invested.

The chairman emeritus of Tata Sons has so far invested in over a dozen start-ups since he retired from the group in December 2012 and all his investments are routed through his investment company RNT Associates. Some of his investments include Ola, Paytm, Snapdeal, CureFit, Urban Ladder and Avanti Finance.

Generic Aadhaar sources generic drugs directly from manufacturers and sells it to retailers, eliminating 16-20 per cent wholesaler margins.

The start-up boasts of an annual revenue of Rs 6 crore and is looking at a revenue of Rs 150-200 crore in the next three years, the statement said. It also claimed to have employed about 55 persons, including pharmacists, IT engineers and marketing professionals.

Deshpande plans to partner with 1,000 pharmacies on a franchisee-based model and expand his reach to Gujarat, Tamil Nadu, Andhra, Delhi, Goa and Rajasthan.

Generic Aadhaar will provide all the support to the unorganised sector by bringing the right technology, IT infrastructure and branding to the forefront.

"Our business model gives us an edge over others as we aim to bring affordable healthcare to millions. Our mission is to provide senior citizens and pensioner the care they deserve by delivering inexpensive medicines," says Deshpande.

Currently, it supplies diabetes and hypertension drugs but will soon start offering cancer drugs also at rates lower than the market price and has also tied up with four WHO-GMP certified manufacturers at Palghar, Ahmedabad, Puducherry and Nagpur.

It provides quality and affordable medicines directly from WHO-GMP facility and has tied up with 30 retailers from Mumbai, Pune, Bengaluru and Odisha following a profit-sharing model.

"Tata got impressed with our business plan and decided to be a part of this mission in a personal capacity and help Generic Aadhaar to reach more and more poor people," Arjun Deshpande, founder and chief executive officer of the start-up, said.

Generic Aadhaar steps in to solve this problem as it aims to partner with 1,000 pharmacies on a franchisee-based model in the coming months and expand their reach to markets such as Gujarat, Tamil Nadu, Andhra Pradesh, New Delhi.

Generic Aadhaar supplies diabetes and hypertension drugs but will soon start offering cancer drugs at rates much lower than the market price.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, May 07 2020. 22:28 IST